Go Pro
NYSE:KVUE

Kenvue Q4 2025 Earnings Report

Kenvue logo
$17.82 +0.21 (+1.16%)
Closing price 03:59 PM Eastern
Extended Trading
$17.68 -0.14 (-0.76%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue EPS Results

Actual EPS
$0.27
Consensus EPS
$0.22
Beat/Miss
Beat by +$0.05
One Year Ago EPS
$0.26

Kenvue Revenue Results

Actual Revenue
$3.78 billion
Expected Revenue
$3.68 billion
Beat/Miss
Beat by +$95.25 million
YoY Revenue Growth
+3.20%

Kenvue Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Tuesday, February 17, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Kenvue's Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kenvue Earnings Headlines

EU extends review of Kimberly-Clark’s $40B Kenvue deal
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Kenvue Inc's Dividend Analysis
See More Kenvue Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kenvue? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kenvue and other key companies, straight to your email.

About Kenvue

Kenvue (NYSE:KVUE) is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health. Kenvue products are sold through retailers, pharmacies, e-commerce channels and other distribution networks in markets around the world.

Kenvue was formed from the consumer health business of Johnson & Johnson and became a publicly traded company on the New York Stock Exchange in 2023. Johnson & Johnson completed the separation of Kenvue as an independent company in 2024. Kenvue is headquartered in Skillman, New Jersey, and is led by Chief Executive Officer Thibaut Mongon.

View Kenvue Profile